Altre lingue NKGen Biotech, Inc.

Azioni

NKGN

US65488A1016

Prezzo di chiusura Nasdaq Altri mercati azionari 00:00:00 15/05/2024			Variaz. 5gg	Var. 1 gen.
1,14 ^USD	0,00%		-9,52%	-58,55%

29/04	Nkgen Biotech annuncia l'approvazione da parte della FDA della domanda di sperimentazione di nuovi farmaci (IND) per la terapia con cellule NK SNK01 nella malattia di Parkinson	CI
18/04	NKGen Biotech, Inc. annuncia la prossima presentazione della terapia a base di cellule NK SNK01 nella malattia neurodegenerativa, in occasione del 12° Summit annuale sullo sviluppo di farmaci per l'Alzheimer e il Parkinson.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition	16/05
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease	29/04
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	29/04
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	29/04
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	25/04
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting	25/04
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit	19/04
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	18/04
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	18/04
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs	11/04
NKGen Biotech, Inc. announced that it has received $5 million in funding	05/04
NKGen Biotech, Inc. announced that it has received $0.5 million in funding from AJB Capital Investments LLC, Sandia Investment Managment LP, Diametric Capital, LP	01/04
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's disease at the Tau2024 Global Conference	26/03
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference	25/03
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	25/03
NKGen Biotech, Inc. announced that it expects to receive $0.33 million in funding from FirstFire Capital Management LLC	21/03
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board	20/03
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference	04/03
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee	08/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NKGen Biotech, Inc.

Azioni

NKGN

US65488A1016

Altre lingue

Filtri